Vasculitis & polymyalgia rheumatica
Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre
Authors' conclusion
Baricitinib 4 mg daily is effective for refractory TAK and is well tolerated.
Study context
- Population
- Patients with refractory TAK, tertiary referral centre; median age 28 (IQR=22–37) years, median disease duration 50 (IQR=24–65) months
- Participants
- 10 patients
- Outcome
- Overall treatment response
- Follow-up
- 6 months
Methodological detailssingle-group, tertiary referral centre
- Single-group
- Tertiary referral centre
Main finding
As reported in the abstract
Baricitinib
60%
6 of 10
Observational data: associations, not effects.
Further findings
Maintained overall treatment response · average follow-up of 15.3 (range 4-31) months
- Patients who maintained overall treatment response
- 4/10 (40%)
GC dose tapered or maintained with no change of combined csDMARDs
- Patients who tapered or maintained the same GC dose
- 8/10 (80%)
GC discontinuation
- Patients who discontinued glucocorticoids (GCs) at 18 and 24 months and were in continuous remission till the end of the study
- 2
Safety
| Outcome | Values |
|---|---|
| Baricitinib withdrawal due to liver dysfunction | Baricitinib 1 events |
Original publication
Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre. RMD Open. Published 22 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →